Results 181 to 190 of about 602,703 (227)
The Relationship Between (Endo)cannabinoids, the Microbiome and Melanoma. [PDF]
Javid FA +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Cannabinoid CB1 Receptor in Schizophrenia
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021Converging lines of evidence from epidemiological, preclinical, and experimental studies indicate that the endocannabinoid system may be involved in the pathophysiology of schizophrenia and suggest that the cannabinoid CB1 receptor may be a potential therapeutic target.
Faith Borgan +2 more
openaire +3 more sources
Internalization and Recycling of the CB1 Cannabinoid Receptor [PDF]
Abstract : Tolerance develops rapidly to cannabis, cannabinoids, and related drugs acting at the CB1 cannabinoid receptor. However, little is known about what happens to the receptor as tolerance is developing. In this study, we have found that CB1 receptors are rapidly internalized following agonist binding and receptor activation ...
Ken Mackie
exaly +3 more sources
2022
Type-1 cannabinoid receptor (CB1), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both the central nervous system and peripheral tissues. Today, its biochemical identification and pharmacological characterization, as well as the screening of thousands of novel ligands that might be ...
Gasperi V, Savini I, Catani MV
openaire +3 more sources
Type-1 cannabinoid receptor (CB1), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both the central nervous system and peripheral tissues. Today, its biochemical identification and pharmacological characterization, as well as the screening of thousands of novel ligands that might be ...
Gasperi V, Savini I, Catani MV
openaire +3 more sources
Behavioural Pharmacology, 2005
It is well established that Cannabis sativa can increase appetite, particularly for sweet and palatable foods. In laboratory animals, cannabinoid CB1 receptor antagonism decreases motivation for palatable foods, and most recently, the CB1 receptor antagonist SR141716A, or rimonabant (Acomplia), was reported to produce weight loss in obese human ...
S J, Ward, L A, Dykstra
openaire +2 more sources
It is well established that Cannabis sativa can increase appetite, particularly for sweet and palatable foods. In laboratory animals, cannabinoid CB1 receptor antagonism decreases motivation for palatable foods, and most recently, the CB1 receptor antagonist SR141716A, or rimonabant (Acomplia), was reported to produce weight loss in obese human ...
S J, Ward, L A, Dykstra
openaire +2 more sources
CB1 Cannabinoid Receptor Ligands
Mini-Reviews in Medicinal Chemistry, 2005The CB1 receptor is expressed in the central nervous system and numerous other tissues including heart, lung and uterus and has been recognized as an important therapeutic target for pain, appetite modulation, glaucoma, multiple sclerosis and other indications.
Ganesh A, Thakur +2 more
openaire +2 more sources
2016
Type-1 cannabinoid receptor (CB1), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both central nervous system and peripheral tissues. Today, its biochemical identification and pharmacological characterization, as well as the screening of thousands of novel ligands that might be useful ...
Catani, VM, GASPERI, VALERIA
openaire +4 more sources
Type-1 cannabinoid receptor (CB1), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both central nervous system and peripheral tissues. Today, its biochemical identification and pharmacological characterization, as well as the screening of thousands of novel ligands that might be useful ...
Catani, VM, GASPERI, VALERIA
openaire +4 more sources
Aminopyrazine CB1 receptor inverse agonists
Bioorganic & Medicinal Chemistry Letters, 2008A series of 5,6-diaryl-2-amino-pyrazines were prepared and found to have antagonist-like properties at the CB1 receptor. Subsequent SAR studies optimized both receptor potency and drug-like properties including solubility and Cytochrome-P450 inhibition potential.
David J, Wustrow +14 more
openaire +2 more sources
Diaryl piperidines as CB1 receptor antagonists
Bioorganic & Medicinal Chemistry Letters, 2010The syntheses and SAR investigations of novel CB(1) receptor antagonists based on a 1,2-diaryl piperidine core have been described. Optimization of this core afforded a compound with robust in vivo potency by reducing food intake in a mouse DIO model.
Jack D, Scott +13 more
openaire +2 more sources

